ASAP3 disrupts ASAP1-ARHGAP12 to inhibit RhoA and yes-associated protein/transcriptional coactivator with PDZ-binding motif, suppressing gastric cancer progression
World Journal of Gastrointestinal Oncology · 25.05.2026
DOI: 10.4251/wjgo.117876 ↗Kurz gefasst
Fachartikel in der Zeitschrift World Journal of Gastrointestinal Oncology, online erschienen am 25.05.2026. Verfasst von Xian-Bin Huang und 4 weiteren Autor:innen.
Abstract (Originalsprache)
BACKGROUND Gastric cancer (GC) has high global mortality, with limited efficacy of advanced therapies due to unclear pathogenesis. While other ASAP family members like ASAP1 are recognized oncoproteins, the role of ASAP3 in GC is poorly understood. AIM To investigate the functions and mechanisms of ASAP3 in GC. METHODS The biological effects of ASAP3 were assessed in vitro using AGS and HGC-27 GC cell lines with ASAP3 overexpression or knockdown, evaluating proliferation, apoptosis, migration, and invasion. A subcutaneous xenograft model was used for in vivo validation. Underlying mechanisms were explored via transcriptomics, proteomics, and molecular biology techniques including co-immunoprecipitation and RhoA activation pull down. RESULTS ASAP3 expression in HGC-27 cells was significantly higher than that in AGS cells. Functional experiments demonstrated that ASAP3 overexpression suppressed GC cell proliferation, migration, invasion, induced S arrest/apoptosis, and inhibited tumor growth, while its knockdown promoted these malignant phenotypes. Then, transcriptomic and proteomic analyses respectively identified 382/714 differentially expressed messenger RNAs and 98/66 differential expressed proteins between short hairpin (sh)-ASAP3 -HGC-27/over-expression (oe)-ASAP3 -AGS and sh-negative control (NC)-HGC-27/oe-NC-AGS cells, which significantly enriched in Hippo pathway, and GTPase regulation. Real-time quantitative polymerase chain reaction showed ASAP3 silencing in HGC-27 cells upregulated CCN1 , AMOTL2 while downregulated CCN2 , while ASAP3 overexpression in AGS cells reversed these trends. Western blot further showed ASAP3 silencing reduced the phosphorylation of MST1 /MST2 , LATS1 /LATS2 , yes-associated protein (YAP), and transcriptional coactivator with PDZ -binding motif (TAZ), whereas ASAP3 overexpression in AGS cells enhanced their phosphorylation. Finally, ASAP3 overexpression could inhibit RhoA activity and thus suppress YAP/TAZ activation by interfering with the ASAP1 -ARHGAP12 interaction. CONCLUSION ASAP3 may inhibit GC oncogenesis/progression by disrupting ASAP1 -ARHGAP12 to suppress RhoA /YAP/TAZ, serving as a potential GC therapeutic target.
Zitieren
APA
Huang, X., Deng, Y., Gong, S., Yu, M., & Cai, H. (2026). ASAP3 disrupts ASAP1-ARHGAP12 to inhibit RhoA and yes-associated protein/transcriptional coactivator with PDZ-binding motif, suppressing gastric cancer progression. World Journal of Gastrointestinal Oncology. https://doi.org/10.4251/wjgo.117876
Vancouver
Huang X, Deng Y, Gong S, Yu M, Cai H. ASAP3 disrupts ASAP1-ARHGAP12 to inhibit RhoA and yes-associated protein/transcriptional coactivator with PDZ-binding motif, suppressing gastric cancer progression. World Journal of Gastrointestinal Oncology. 2026. doi:10.4251/wjgo.117876
BibTeX
@article{Huang2026,
author = {Huang, Xian-Bin and Deng, Yuan and Gong, Shi-Yi and Yu, Miao and Cai, Hui},
title = {ASAP3 disrupts ASAP1-ARHGAP12 to inhibit RhoA and yes-associated protein/transcriptional coactivator with PDZ-binding motif, suppressing gastric cancer progression},
journal = {World Journal of Gastrointestinal Oncology},
year = {2026},
doi = {10.4251/wjgo.117876}
}
EUVIMED